Q. Lu et al., THE EFFECTS OF AROMATASE INHIBITORS AND ANTIESTROGENS IN THE NUDE-MOUSE MODEL, Breast cancer research and treatment, 50(1), 1998, pp. 63-71
The effects of antiestrogens, tamoxifen and ICI 182,780, and aromatase
inhibitors, arimidex (anastrozole ZD1033) and letrozole (CGS 20,267),
on the growth of tumors were studied in nude mice. In this model, est
rogen dependent MCF-7 human breast cancer cells stably transfected wit
h the aromatase gene were inoculated in four sites per mouse. Sufficie
nt estrogen is produced from aromatization of androstenedione suppleme
nt (0.1 mg/mouse/day) by the cells to stimulate their proliferation, t
umor formation, and maintain the uterus similar to that of the intact
mouse. Once the tumors reached a measurable size, the mice were inject
ed with antiestrogen or inhibitor for 35-56 days. Tumor volumes were m
easured weekly. At autopsy, the tumors were removed, cleaned, and weig
hed. Statistical data was determined from tumor weights. Both antiestr
ogens were effective in reducing tumor growth in these mice. Tamoxifen
appears to be more effective than ICI 182,780, although the former st
imulated the uterine weight whereas the pure antiestrogen did not. How
ever, both aromatase inhibitors were more effective than the antiestro
gens. Tumor regression was observed with letrozole. Thus, after-treatm
ent tumor weights were less than those of a group of mice at the start
of treatment. The aromatase inhibitors also reduced the weight of the
uterus, suggesting that these compounds, as well as the pure antiestr
ogen, may not cause endometrial proliferation, unlike tamoxifen. These
aromatase inhibitors may not only benefit patients who have relapsed
from tamoxifen, but may be more effective in patients as first line ag
ents for suppressing the effects of estrogen.